(State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer | ||||||
incorporation or organization) | Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
Name and title | Base Salary | Target Bonus (% of Base Salary) | ||||||
Matthew Korenberg, President and Chief Operating Officer | $540,000 | 50% | ||||||
Octavio Espinoza, Chief Financial Officer | $400,000 | 40% |
LIGAND PHARMACEUTICALS INCORPORATED | |||||
Date: December 14, 2022 | By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary |
Cover Page |
Dec. 13, 2022 |
---|---|
Cover [Abstract] | |
Entity Central Index Key | 0000886163 |
Amendment Flag | false |
Document Type | 8-K |
Document Period End Date | Dec. 13, 2022 |
Entity Registrant Name | LIGAND PHARMACEUTICALS INC |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-33093 |
Entity Tax Identification Number | 77-0160744 |
Entity Address, Address Line One | 3911 Sorrento Valley Boulevard, Suite 110 |
Entity Address, City or Town | San Diego |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92121 |
City Area Code | 858 |
Local Phone Number | 550-7500 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | LGND |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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end
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end